Vertex CF Combo Succeeds In Phase III, But Secondary Endpoints May Be Crucial
This article was originally published in The Pink Sheet Daily
Executive Summary
Vertex’s two-drug combo for cystic fibrosis hits primary and several key secondary endpoints in a pair of pivotal trials, although data from the primary endpoint underwhelms some observers. Strong data from a pair of secondary endpoints, however, may provide real-world strategic value for the combo.